Catatan sumber primer
PenentuHasil topline
AVTX-009 Fase 2 Uji Coba LOTUS pada HS: data topline diperkirakan Q2 2026
Avalo telah menyelesaikan pendaftaran dalam uji coba Fase 2 LOTUS AVTX-009 pada hidradenitis suppurativa. Hasil topline kini dipandu untuk Q2 2026, menetapkan tonggak regulasi/klinis berikutnya untuk aset tersebut.
Fakta utama
- Diajukan
- 2 Des 2025, 11.38
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
AVTXAvalo Therapeutics- Aset
- AVTX-009
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,
Selengkapnya tentang aset ini
Penting
10 Okt 2025
11.01
AVTXAvalo TherapeuticsAVTX-009 Uji Coba Fase 2 LOTUS pada HS sedang merekrut; data topline pertengahan 2026